RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives

Thumbnail
2023
Guidelines_to_Analyze_Preclinical_Studies_Using_Perinatal_Derivatives_2023.pdf (1.522Mb)
Authors
Pires, Ana Salomé
Bollini, Sveva
Botelho, Maria Filomena
Lang-Olip, Ingrid
Ponsaerts, Peter
Balbi, Carolina
Lange-Consiglio, Anna
Fénelon, Mathilde
Mojsilović, Slavko
Berishvili, Ekaterine
Cremonesi, Fausto
Gazouli, Maria
Bugarski, Diana
Gellhaus, Alexandra
Kerdjoudj, Halima
Schoeberlein, Andreina
Article (Published version)
Metadata
Show full item record
Abstract
The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or ameliorati...on of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.

Keywords:
perinatal derivatives / preclinical studies / animal models / database search / consensus / protocol
Source:
Methods and Protocols, 2023, 6, 3, 45-
Publisher:
  • Multidisciplinary Digital Publishing Institute (MDPI)
Funding / projects:
  • University of Genova, Curiosity Driven Grant “TriggeringCARDIOmyocyte renewal by harnessing the STem cell pARacrine potential (CARDIO-STAR)”
  • Foundation for Science and Technology (Portugal) through the Strategic ProjectUIDB/04539/2020 and UIDP/04539/2020 (CIBB)
  • University of Geneva, Horizon 2020 Framework Program (VANGUARD 874700)

DOI: 10.3390/mps6030045

ISSN: 2409-9279

[ Google Scholar ]
URI
http://rimi.imi.bg.ac.rs/handle/123456789/1297
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Pires, Ana Salomé
AU  - Bollini, Sveva
AU  - Botelho, Maria Filomena
AU  - Lang-Olip, Ingrid
AU  - Ponsaerts, Peter
AU  - Balbi, Carolina
AU  - Lange-Consiglio, Anna
AU  - Fénelon, Mathilde
AU  - Mojsilović, Slavko
AU  - Berishvili, Ekaterine
AU  - Cremonesi, Fausto
AU  - Gazouli, Maria
AU  - Bugarski, Diana
AU  - Gellhaus, Alexandra
AU  - Kerdjoudj, Halima
AU  - Schoeberlein, Andreina
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1297
AB  - The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Methods and Protocols
T1  - Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives
IS  - 3
SP  - 45
VL  - 6
DO  - 10.3390/mps6030045
ER  - 
@article{
author = "Pires, Ana Salomé and Bollini, Sveva and Botelho, Maria Filomena and Lang-Olip, Ingrid and Ponsaerts, Peter and Balbi, Carolina and Lange-Consiglio, Anna and Fénelon, Mathilde and Mojsilović, Slavko and Berishvili, Ekaterine and Cremonesi, Fausto and Gazouli, Maria and Bugarski, Diana and Gellhaus, Alexandra and Kerdjoudj, Halima and Schoeberlein, Andreina",
year = "2023",
abstract = "The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Methods and Protocols",
title = "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives",
number = "3",
pages = "45",
volume = "6",
doi = "10.3390/mps6030045"
}
Pires, A. S., Bollini, S., Botelho, M. F., Lang-Olip, I., Ponsaerts, P., Balbi, C., Lange-Consiglio, A., Fénelon, M., Mojsilović, S., Berishvili, E., Cremonesi, F., Gazouli, M., Bugarski, D., Gellhaus, A., Kerdjoudj, H.,& Schoeberlein, A.. (2023). Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols
Multidisciplinary Digital Publishing Institute (MDPI)., 6(3), 45.
https://doi.org/10.3390/mps6030045
Pires AS, Bollini S, Botelho MF, Lang-Olip I, Ponsaerts P, Balbi C, Lange-Consiglio A, Fénelon M, Mojsilović S, Berishvili E, Cremonesi F, Gazouli M, Bugarski D, Gellhaus A, Kerdjoudj H, Schoeberlein A. Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols. 2023;6(3):45.
doi:10.3390/mps6030045 .
Pires, Ana Salomé, Bollini, Sveva, Botelho, Maria Filomena, Lang-Olip, Ingrid, Ponsaerts, Peter, Balbi, Carolina, Lange-Consiglio, Anna, Fénelon, Mathilde, Mojsilović, Slavko, Berishvili, Ekaterine, Cremonesi, Fausto, Gazouli, Maria, Bugarski, Diana, Gellhaus, Alexandra, Kerdjoudj, Halima, Schoeberlein, Andreina, "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives" in Methods and Protocols, 6, no. 3 (2023):45,
https://doi.org/10.3390/mps6030045 . .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB